53 active shortage notices across 7 countries.
Last updated 17 Sept 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Australia | critical | 1 | 8 Nov 2024 | 25 Dec 2026 | TGA |
| Netherlands | medium | 17 | 16 Mar 2026 | — |
| Canada | medium | 15 | 14 Oct 2016 | 3 Jan 2028 | HC |
| Belgium | medium | 12 | 3 May 2024 | 10 Mar 2027 | FAMHP |
| Germany | medium | 6 | 11 Jul 2025 | 30 Jun 2026 | BfArM |
| Bosnia and Herzegovina | medium | 1 | 19 Jun 2026 | 31 Aug 2026 | ALMBIH |
| Italy | medium | 1 | 12 Mar 2026 | — | AIFA |
Clinically related options from Mederti's curated alternatives data. Always confirm suitability with a pharmacist or prescriber before substituting.
Yes. As of the latest regulator updates, Zolmitriptan has 53 active shortage notices across 7 countries (Australia, Netherlands, Canada, Belgium, Germany, Bosnia and Herzegovina and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Zolmitriptan shortages to causes not stated by the regulator, raw-material (API) supply problems, manufacturing problems. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 30 Dec 2022 to 3 Jan 2028, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Mederti lists 6 clinically related alternatives for Zolmitriptan (see the alternatives section above). Alternatives require clinical judgement — always confirm suitability with a pharmacist or prescriber and your national guidance before substituting.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Erenumab · Eletriptan · Rizatriptan · Sumatriptan-Succinate · Almotriptan · Dihydroergotamine
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.